# A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

> **NCT07474727** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Multitude Therapeutics Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** AMT-676
- **DRUG:** 5-FU
- **DRUG:** Leucovorin
- **DRUG:** Bevacizumab
- **DRUG:** Cetuximab
- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT07474727
- **Lead sponsor:** Multitude Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-02-28
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07474727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07474727, "A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT07474727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*